SG3 Management’s Atossa Therapeutics ATOS Stock Holding History

SG3 Management’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-167	Closed	-$9.71K	–	989
2021 Q2	$16K	Sell	167 -333	-67%	-$17.6K	﹤0.01%	967
2021 Q1	$16K	Buy	+500	New	+$18.3K	﹤0.01%	1116

Other funds holding ATOS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SG3 Management's ATOS Position: Q3 2021 in Review

SG3 Management sold out of Atossa Therapeutics (ATOS) in Q3 2021, closing a stake of 167 shares — an estimated $9.71K sold.

SG3 Management first reported a position in ATOS in Q1 2021 and held it in 2 quarters. The position peaked at $16K in Q2 2021. 93 funds tracked by Wall St. Rank hold ATOS as of Q3 2021.

SG3 Management reported no remaining Atossa Therapeutics position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 167 Atossa Therapeutics shares in Q3 2021, an estimated $9.71K.
SG3 Management first reported a position in Atossa Therapeutics in Q1 2021 and held it in 2 quarters.
SG3 Management's Atossa Therapeutics position peaked at $16K in Q2 2021.
93 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.